CD8A and neoplasm: By genetically engineering DCs, such as creating DC-Ad-CCL21 via adenovirus vectors, it is possible to increase CD8+ T cell infiltration at tumor sites, enhance T cell immunity and elevate PD-L1 mRNA expression in mouse bronchoalveolar cell carcinoma.511 This complements ICB therapies to ensure the effectiveness of anti-tumor immunotherapy.